DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
MWN-AI** Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) recently announced a key opinion leader (KOL) webinar scheduled for May 28, 2025, at 8 AM ET to discuss DM199 (rinvecalinase alfa), its investigational treatment for preeclampsia. The event will focus on the existing challenges in treating this serious pregnancy-related vascular disorder, which currently lacks approved therapeutics, and will highlight the clinical trial design and endpoints for DM199's Phase 2 study.
Prominent speakers including Professors Stephen Tong and Susan Walker from The University of Melbourne, and Professor Baha Sibai from the University of Texas will share their expertise regarding preeclampsia, a condition affecting up to 8% of pregnancies globally and associated with significant maternal and fetal risks. These experts will delve into the treatment landscape and unmet needs that underline the importance of developing effective therapies for this condition.
DM199 aims to enhance the body’s ability to produce nitric oxide and other beneficial molecules, which could potentially lower blood pressure, improve endothelial function, and enhance blood flow to crucial maternal and fetal organs. The live webinar will include a Q&A session allowing participants to engage directly with the speakers.
DiaMedica’s commitment to addressing serious ischemic diseases, including acute ischemic stroke and preeclampsia, is underscored by the clinical development of DM199, which represents a novel approach in the treatment landscape. The expert insights during the KOL event are anticipated to shed light on the potential breakthrough capabilities of DM199 in improving outcomes for women facing this critical health issue.
For those interested in participating, registration details are available on DiaMedica's website.
MWN-AI** Analysis
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) recently announced a significant Key Opinion Leader (KOL) webinar scheduled for May 28, 2025, to discuss its investigational drug DM199 (rinvecalinase alfa) for treating preeclampsia. Given the alarming lack of approved therapies for this serious pregnancy complication, this event is poised to enhance investor interest and potentially boost the stock's performance.
Preeclampsia affects up to 8% of pregnancies globally and poses severe risks to both mothers and infants. With prominent experts—Professors Baha Sibai, Stephen Tong, and Susan Walker—leading the discussion, the webinar promises valuable insights into the current treatment landscape and DM199's clinical trial design. This could validate the therapy's relevance, which is critical, as the lack of approved treatments for preeclampsia represents a significant unmet medical need and market opportunity.
DM199 operates through enhancing nitric oxide and related factors, aiming to improve vascular health and maternal organ perfusion, thus addressing the root of preeclampsia. If future clinical trials demonstrate efficacy and safety, DM199 can position itself as a first-in-class treatment in an untapped market, which could dramatically elevate DiaMedica's valuation.
From an investment perspective, this upcoming KOL event is a crucial catalyst that could drive sentiment and demand for DMAC shares. Investors should closely monitor developments surrounding the clinical trials' outcomes and the insights shared during the webinar. Any positive news or breakthroughs could result in upward share price movement, making DMAC a speculative yet potentially rewarding opportunity in the biopharmaceutical space. Additionally, tracking institutional interest and strategic collaborations will provide further context for long-term investment considerations.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Company to Host Preeclampsia Key Opinion Leader Event May 28, 2025 at 8 AM Eastern / 7 AM Central
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study.
The webinar will feature Prof. Stephen Tong, MD, PhD (The University of Melbourne), Prof. Susan Walker, MD, PhD (The University of Melbourne), and Prof. Baha Sibai, MD (University of Texas) who will discuss the unmet need and current treatment landscape for preeclampsia (PE), a life-threatening pregnancy associated vascular disorder with no approved therapeutics. This will be followed by the Phase 2, proof-of-concept, clinical trial design and endpoints of DM199 in PE. DM199, through enhancing the body’s natural ability to produce nitric oxide, prostacyclin and endothelium-derived hyper polarizing factor, has the potential to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
A live question and answer session will follow the formal presentations.
To register, click here .
About Professor Baha Sibai
Dr. Baha M. Sibai is a globally recognized expert in Maternal-Fetal Medicine and Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at McGovern Medical School, UTHealth Houston. He directs the nation’s largest Maternal-Fetal Medicine fellowship program and maintains active clinical practices at Memorial Hermann–Texas Medical Center and Lyndon B. Johnson Hospital. Renowned for his groundbreaking work in hypertensive disorders of pregnancy, Dr. Sibai has authored over 750 peer-reviewed articles and numerous textbook chapters. He developed key diagnostic criteria for hypertensive conditions, including HELLP syndrome, and pioneered protocols for managing severe preeclampsia.
Dr. Sibai has received major honors, including the Society for Maternal-Fetal Medicine’s Lifetime Achievement Award and ACOG’s 2018 Hall of Fame All-Star status. He is a founding member and past president of both the North American and International Societies for the Study of Hypertension in Pregnancy, and a long-standing contributor to the NIH-funded MFM Units Network. With decades of NIH and CDC grant support, he has led numerous multicenter clinical trials. From 1995 to 2013, he served as an examiner for the American Board of Obstetrics and Gynecology. Dr. Sibai remains a leading voice in advancing maternal care, particularly in complex and high-risk pregnancies.
About Professor Stephen Tong
Professor Stephen Tong is listed in Expertscape as one of the top 10 preeclamptic experts in the world. He is a key opinion leader in preeclampsia, having penned invited reviews or commentaries about the disease in the world’s most prestigious scientific journals.
Dr Tong is jointly trained as an OB (Mercy Hospital for Women) and laboratory scientist (Professorial Fellow, University of Melbourne). Dr. Tong has a strong interest in translational research - developing therapeutics to tackle major pregnancy complications and has had a lead role in taking four therapeutic concepts identified in his laboratory to phase I-III clinical trials run across the globe – UK, New Zealand, South Africa, the Netherlands and Sweden.
Dr. Tong has authored 250 papers, 100+ on preeclampsia, and published original research as the first or senior author in the world’s premier journals – Nature, The Lancet, British Medical Journal, Nature Communications, JAMA Pediatrics, JAMA Psychiatry and others. Dr. Tong is chair of the advisory board of the Robinson Research Institute in Adelaide, Australia; Co-Director of Mercy Perinatal; Research Director at Mercy Hospital for Women; awarded three prestigious National Health and Medical Research Council national awards for his research and has received over $10 million in competitive grant funding.
About Professor Susan Walker
Professor Sue Walker is the inaugural Sheila Handbury Chair of Maternal Fetal Medicine, Head of the Department of Obstetrics, Gynaecology and Newborn Health at University of Melbourne and Divisional Chair, Perinatal Medicine at Mercy Hospital for Women (Mercy). Dr. Walker’s research program positions her as an international leader in the areas of Fetal Growth Restriction (ranked 17 th globally in Expertscape) and on the 99th centile in the field of preeclampsia (SciVal Benchmarking). Among Dr. Walker’s 240+ publications are contributions in the leading biomedical journals - Lancet, New England Journal of Medicine, British Medical Journal and others.
Dr. Walker is a Maternal Fetal Medicine sub-specialist, tasked with providing care for some of the highest risk pregnancies. Her research program is focused on improving detection and treatment of two leading complications in pregnancy responsible for countless maternal and infant deaths: preeclampsia and fetal growth restriction. In recognition of Dr. Walker’s roles in clinical care, research, professional leadership and education, Dr. Walker was made an Officer, Order of Australia in 2018, a Fellow of the Academy of Health and Medical Science in 2023 and awarded the Women’s Healthcare Australasia Medal of Distinction in 2023.
About Preeclampsia
Preeclampsia is a serious pregnancy disorder that typically develops after the 20th week of gestation, characterized by high blood pressure and damage to organ systems, often the kidneys and liver. Affecting up to 8% of pregnancies worldwide, preeclampsia can pose significant risks to both the mother and baby, including risk of stroke, placental abruption, progression to eclampsia, premature delivery, and death. Symptoms may include severe headaches, vision changes, upper abdominal pain and swelling in the hands and face. Delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia. Women who have had preeclampsia have three to four times the risk of high blood pressure and double the risk for heart disease and stroke.
About DM199 (rinvecalinase alfa)
DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for acute ischemic stroke and preeclampsia. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor. In preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250519893700/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
FAQ**
How is DiaMedica Therapeutics Inc. (DMAC) positioned in comparison to existing treatments for preeclampsia, given the current lack of approved therapeutics in this area?
What specific clinical trial endpoints will be evaluated in the DM199 Phase 2 study, and how do these align with the unmet needs in treating preeclampsia as discussed by key opinion leaders at DiaMedica Therapeutics Inc. (DMAC)?
What are the anticipated outcomes of the DM199 clinical trial for preeclampsia, and how might they impact the future treatment landscape according to DiaMedica Therapeutics Inc. (DMAC)?
Can DiaMedica Therapeutics Inc. (DMAC) elaborate on the mechanism of action of DM199 and its potential effect on maternal and fetal health outcomes in the context of preeclampsia?
**MWN-AI FAQ is based on asking OpenAI questions about DiaMedica Therapeutics Inc. (NASDAQ: DMAC).
NASDAQ: DMAC
DMAC Trading
-2.88% G/L:
$6.41 Last:
59,270 Volume:
$6.40 Open:
